[Hong Kong, August 28, 2019] Recently, Pang Xinchao, the Executive Deputy Director of Standing Committee of the Dongguan Municipal People's Congress, and Zhao Yi, the Deputy Director of Dongguan Municipal Human Resources and Social Security Bureau, and Deng Weijie, the Chief of Technology Transformation and Regional Innovation Sector of Dongguan Municipal Science and Technology Bureau, and Zhu Mohe, the Vice Secretary of the Changping Town Party Committee, led the team to visit high-end talent in Great Bay Bio, and to exchange ideas.

Dr. Chen Liang, the CEO of Great Bay Bio, and Dr. Wang Yonggang, the Vice President, and others warmly welcomed visitors and showed them around the company R&D center, the office area, etc. Dr. Chen Liang introduced company, recent development status, and future planning in the conference for visitors, and showed the blueprint that Great Bay Bio could solve two big headaches in the biotechnology industry with its unprecedented AI + biotechnology development team and platform. With such, Great Bay Bio could disruptively shorten timeline for drug development, dramatically lower development cost. Dr. Wang Yonggang gave visitors detailed introduction for R&D innovative technology, and received very positive feedback. Officers after conference showed thanks for and compliment the Great Bay Bio for its high-end management team and R&D capability; Pang Xinchao are very pleased that overseas returnees to start up business with their new technology and ideas, and has high expectation for Great Bay Bio which is answering the development of Great Bay Area greatly supported by the Government.

About GBB

Headquartered in Hong Kong, Great Bay Bio (GBB) is a high-tech enterprise dedicated to applying artificial intelligence and other cutting-edge technologies to biopharmaceutical development and other blue ocean bio-products, ultimately solving numerous pain points of biopharmaceutical industry, including high failure rates, long development timeline and high costs. Since the company’s establishment, it has obtained massive data from conventional biologics development in its 3000 m² CMC facilities which bolster advance equipment from world-renowned manufacturers. GBB has also successfully brought a number of biologic products to NDA stage, some of which are classified as national class I innovative drugs. Currently, the company has created the intelligent centralized database, where deep learning is being performed to create next generation of AI-enabled bioprocessing ecosystem. To learn more, please visit http://www.greatbay-bio.com.